{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T07:51:00Z","timestamp":1648885860350},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T00:00:00Z","timestamp":1498262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s11739-017-1688-7","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:20:24Z","timestamp":1498278024000},"page":"561-563","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes"],"prefix":"10.1007","volume":"12","author":[{"given":"Davide","family":"Imberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mastroiacovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,24]]},"reference":[{"key":"1688_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T Hulle Van der","year":"2014","unstructured":"Van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320\u2013328","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1688_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11739-015-1249-x","volume":"10","author":"F Dentali","year":"2015","unstructured":"Dentali F, Di Minno MN, Gianni M, Ambrosino P, Squizzato A, Ageno W (2015) Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Intern Emerg Med 10(4):507\u2013514","journal-title":"Intern Emerg Med"},{"issue":"7","key":"1688_CR3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s11739-016-1521-8","volume":"11","author":"D Imberti","year":"2016","unstructured":"Imberti D, Pomero F, Benedetti R, Fenoglio L (2016) Safety and efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Intern Emerg Med 11(7):895\u2013900","journal-title":"Intern Emerg Med"},{"issue":"1","key":"1688_CR4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","volume":"41","author":"AE Burnett","year":"2016","unstructured":"Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J (2016) Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41(1):206\u2013232","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"1688_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.21037\/cdt.2016.11.17","volume":"6","author":"S Madan","year":"2016","unstructured":"Madan S, Shah S, Dale P, Partovi S, Parikh SA (2016) Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther 6(6):570\u2013581","journal-title":"Cardiovasc Diagn Ther"},{"issue":"15","key":"1688_CR6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"Hokusai-VTE Investigators, B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415","journal-title":"N Engl J Med"},{"issue":"11","key":"1688_CR7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjmed.2016.05.041","volume":"129","author":"ME Barra","year":"2016","unstructured":"Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ (2016) Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med 129(11):1198\u20131204","journal-title":"Am J Med"},{"issue":"2","key":"1688_CR8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1160\/TH16-07-0494","volume":"117","author":"J Trujillo-Santos","year":"2017","unstructured":"Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, D\u00edaz-Peromingo JA, N\u00fa\u00f1ez MJ, Ca\u00f1as I, Mastroiacovo D, Saraiva de Sousa M, Monreal M, Investigators RIETE (2017) Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 117(2):382\u2013389","journal-title":"Thromb Haemost"},{"key":"1688_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/asheducation-2015.1.125","volume":"2015","author":"ESN Van","year":"2015","unstructured":"Van ESN, B\u00fcller HR (2015) Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations. Hematol Am Soc Hematol Educ Program 2015:125\u2013131","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1688_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.phrs.2016.06.023","volume":"118","author":"L Bertoletti","year":"2017","unstructured":"Bertoletti L, Ollier E, Duvillard C, Delavenne X, Beyens MN, De Magalhaes E, Bellet F, Basset T, Mismetti P, Laporte S (2017) Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 118:33\u201342","journal-title":"Pharmacol Res"},{"issue":"4","key":"1688_CR11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1160\/TH16-03-0244","volume":"116","author":"P Verhamme","year":"2016","unstructured":"Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H (2016) Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost 116(4):747\u2013753","journal-title":"Thromb Haemost"},{"issue":"8","key":"1688_CR12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, Investigators AMPLIFY-EXT (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699\u2013708","journal-title":"N Engl J Med"},{"issue":"13","key":"1688_CR13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AW, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MC, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, EINSTEIN CHOICE Investigators (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376(13):1211\u20131222","journal-title":"N Engl J Med"},{"issue":"15","key":"1688_CR14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","volume":"348","author":"PM Ridker","year":"2003","unstructured":"Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, Investigators PREVENT (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425\u20131434","journal-title":"N Engl J Med"},{"key":"1688_CR15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","volume":"349","author":"C Kearon","year":"2013","unstructured":"Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M (2013) Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631\u2013639","journal-title":"N Engl J Med"},{"issue":"2","key":"1688_CR16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153","journal-title":"N Engl J Med"},{"key":"1688_CR17","unstructured":"European Medicine Agency (2014) Pradaxa: EPAR-product information. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/000829\/WC500041059.pdf . Accessed 20 March 2017"},{"issue":"3","key":"1688_CR18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11739-017-1628-6","volume":"12","author":"D Prisco","year":"2017","unstructured":"Prisco D, Ageno W, Becattini C, D\u2019Angelo A, Dav\u00ec G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI (Italian Society of Internal Medicine), FADOI (Federation of Associations of Hospital Doctors on Internal Medicine), SISET (Italian Society for the Study of Haemostasis and Thrombosis) (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12(3):387\u2013406","journal-title":"Intern Emerg Med"},{"issue":"12","key":"1688_CR19","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N Es Van","year":"2014","unstructured":"Van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968\u20131975","journal-title":"Blood"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-017-1688-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T20:07:58Z","timestamp":1569528478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-017-1688-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,24]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1007\/s11739-017-1688-7","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,24]]}}}